Yüklüyor......
EGFR基因少见突变型非小细胞肺癌的临床特征及应用EGFR-TKIs治疗效果评价
BACKGROUND AND OBJECTIVE: Adenocarcinoma is the most common type of lung cancer. It has been clinically evaluated that therapiestargeting against the epidermal growth factor receptor (EGFR) as the clinical standard first-line treatment. The response and outcome of EGFR-tyrosine kinase inhibitors (TK...
Kaydedildi:
| Yayımlandı: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
中国肺癌杂志编辑部
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6533192/ https://ncbi.nlm.nih.gov/pubmed/31109439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2019.05.06 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|